x

Posted 25 September, 2023

Lucira Health, Inc. appointed new CEO

CEO Change detected for ticker OTC:LHDXQ in a 8-K filed on 25 September, 2023.


  Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor's Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company's Board of Directors (the "Board"), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Lucira Health, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Lucira Health, Inc. is a medical technology company, which engages in the business of developing and commercializing transformative and innovative infectious disease test kits. It operates through the following customer segments: the United States Healthcare (US Healthcare), United States Business to Business and Government (US Business to Business and Government), Direct to Consumer (DTC), and International. The US Healthcare segment provides solutions of choice for certain telehealth platforms and providers who are able to confirm diagnosis immediately and over a telehealth platform to drive treatment. The US Business to Business and Government segment is involved in selling OTC test kits to both employers and government organizations. The DTC segment includes selling directly to the individual consumer through online platforms. The International segment focuses on selling tests into Canada, Taiwan, Singapore, and Israel. The company was founded by Debkishore Mitra, John Robert Waldeisen, and Benjamin Ross on February 20, 2013 and is headquartered in Emeryville, CA.
Market Cap
N/A
View Company Details
Relevant filing section
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Pursuant to the terms of the Chapter 11 Plan, on the Effective Date, Brian Ryniker will be appointed as the Liquidating Trustee and representative of the Debtor's Estate, and Erik T. Engelson, President, Chief Executive Officer and member of the Company's Board of Directors (the "Board"), Michael Wyse, member of the Board, and Richard Narido, Chief Financial Officer, will each be deemed to have resigned from their respective positions as directors and officers of the Company.